Changes in the diagnosis and non-invasive treatment of chronic coronary syndromes in the last three European Society of Cardiology guidelines

Izabela Kozłowska1, Przemysław Trzeciak2, Mariusz Gąsior2

1Clinical Department of Hematology and Cancer Prevention, Municipal Hospital, Chorzów, Poland
23rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland

Kardiochirurgia i Torakochirurgia Polska 2021; 18 (2): 105-110

Abstract
One of the most common forms of ischemic heart disease is chronic coronary syndromes (CCS), formerly known as stable coronary artery disease. During the last 15 years, the European Society of Cardiology has modified the guidelines for the diagnosis and treatment of CCS three times. The aim of this study was to analyze the changes in non-invasive diagnostics and pharmacotherapy of CCS that occurred in the last three guidelines. In non-invasive diagnostics, the most important change was reduction of the role of the electrocardiographic exercise test in favor of non-invasive stress imaging tests and computed tomography angiography. In pharmacotherapy, the role of β-blockers and calcium channel blockers has increased in controlling heart rate and symptoms. Intensive hypolipemic treatment for prevention of cardiovascular events and treatment with low doses of novel oral anticoagulants for those at high risk of cardiovascular events with sinus rhythm are among the recommendations.

Key words: chronic coronary syndromes, guidelines, European Society of Cardiology.

Introduction
Ischemic heart disease is a set of symptoms caused by the insufficient supply of oxygen and energy substrates in the heart muscle cells. In 80% of cases it is caused by the formation of atherosclerotic plaque. The atherosclerotic process begins as early as in the first decade of human life in an asymptomatic form, followed by a symptomatic acute form of acute coronary syndrome (ACS) or a chronic form of coronary artery disease (CAD) [1].

In August 2019, the European Society of Cardiology (ESC) released its guidelines for the management of patients with chronic coronary syndromes (CCS). The change of nomenclature was dictated by the fact that the atherosclerotic process is not stable but dynamic. Its natural course may be corrected by the modification of risk factors, pharmacotherapy, or revascularization. Therefore, CAD can manifest itself as CCS, or – in the case of a sudden event such as plaque erosion or rupture leading to myocardial ischemia – as ACS [2].

The new guidelines replaced the former recommendations released by the ESC in 2013 for the management of patients with chronic coronary syndromes (SCAD). Since 2006, when the first guidelines for the management of SCAD appeared, there have been changes not only in the nomenclature but, above all, in the area of diagnosis and treatment.

The aim of this study was to analyze the changes in the ESC recommendations for noninvasive diagnostics and pharmacotherapy of patients with SCAD and CCS over the past 14 years and their impact on the current management strategy in this group of patients.

Non-invasive diagnostics
The initial clinical evaluation of a patient with suspected or diagnosed CAD has not changed in the last three recommendations [2–4]. A resting electrocardiogram should be performed in every patient with suspected or diagnosed CCS, while a chest X-ray is recommended for selected patients (mainly those with atypical pain, those with suspected pulmonary disease, or those with suspected heart failure). Laboratory diagnostics has not changed significantly, either. A peripheral blood count, lipid profile, and creatinine tests should be performed for every patient with suspected CAD, or – in the case of a sudden event such as plaque erosion or rupture leading to myocardial ischemia – as ACS [2].

The new guidelines replaced the former recommendations released by the ESC in 2013 for the management of stable coronary artery disease (SCAD). Since 2006, when the first guidelines for the management of SCAD appeared, there have been changes not only in the nomenclature but, above all, in the area of diagnosis and treatment.
ECG abnormalities such as left bundle branch block (LBBB) or an abnormal Q wave, in patients with abnormalities in the physical examination suggestive of a structural heart disease such as valvular defects or hypertrophic cardiomyopathy, and in patients with symptoms of heart failure [3]. The authors of the 2013 guidelines recommended that echocardiography be performed in all patients with suspected CAD. This test serves risk stratification by allowing the assessment of left ventricular ejection fraction (LVEF) and the identification of segmental wall motion abnormalities that may suggest the presence of CAD. Furthermore, echocardiography allows the exclusion of other causes of angina [4]. Resting echocardiography was included in class I recommendations and credibility level B of the 2019 guidelines [2].

The past 14 years saw a marked change in the role of imaging studies in the diagnosis of CAD and the qualification for coronary angiography, including a decrease in the role of the exercise ECG. In 2006, exercise ECG was the primary diagnostic tool recommended for patients with symptoms of angina and an intermediate or high probability of CAD before testing [I B]. For those unable to exercise or with existing contraindications to exercise, an imaging stress test or computed tomography angiography (CTA) provided an alternative [3].

After noninvasive testing, the authors of guidelines recommended risk stratification and classification of patients into one of three risk groups – low, intermediate, and high – with estimated annual cardiovascular mortality, respectively, at < 1%, 1–2% and > 2%. Coronary angiography was recommended for the high-risk group and, optionally, based on the severity of symptoms and clinical evaluation, for the intermediate-risk group, while conservative treatment was recommended for the low-risk group [3].

The 2013 guidelines introduced a three-step decision-making process for the management of patients with suspected CAD, which included a pre-test probability (PTP) assessment, non-invasive diagnosis, and stratification of subsequent cardiovascular events. The PTP assessment was carried out in line with the estimates of CAD prevalence based on factors such as age, sex, and symptom characteristics (i.e. whether the chest pain is typical, atypical, or nonanginal). A low PTP (< 15%) invoked a recommendation of searching for another cause of symptoms, an intermediate PTP (15–85%) entailed a recommendation of performing noninvasive diagnostic tests, and a high-risk group (PTP > 85%) was recommended to be diagnosed with CAD and referred for coronary angiography [4].

Exercise ECG was recommended as the initial test in patients with an intermediate probability of CAD (I B), although stress test imaging had a similar or better sensitivity and specificity. A non-invasive stress test was recommended as the initial test primarily in patients with abnormalities in their electrocardiograms that prevented the interpretation of the recording during the exercise, as well as in patients with an already established diagnosis of CAD, after previous coronary interventions [4].

The latest 2019 ESC guidelines have significantly altered the previous PTP values. According to a new recommendation, the selection of a method of diagnosing CAD should include, in addition to PTP, the so-called modifiers consisting of, among other things, the results of certain laboratory tests (including a lipid profile, fasting blood glucose, HbA1c), 12-lead ECG, echocardiography, or computed tomography (CT) coronary artery calcification index. Based on PTP and the modifiers, a clinical probability of CAD is established, which determines further management. In high-risk patients with typical angina symptoms, refractory to treatment, occurring at a low exercise intensity, and with a high probability of CAD, coronaryography is recommended. In low- and intermediate-risk patients, non-invasive stress test imaging or CTA is recommended [2]. In this group of patients, exercise ECG has so far been the initial diagnostic test for CAD, unless baseline electrocardiographic changes precluded its interpretation or the patient was unable to perform it for other reasons [3, 4]. The 2019 guidelines reduced the role of ST ECG to class IIb. The authors of the guidelines recommend that this group of patients be diagnosed using non-invasive and stress imaging modalities, such as CTA, stress magnetic resonance imaging (MRI), stress echocardiography, single photon emission tomography, positron emission tomography (PET), and contrast echocardiography [2].

The choice of the type of a noninvasive test should result from an assessment of the clinical probability of CAD (CTA is preferred for low-risk CAD), factors that may influence the outcome, local knowledge, and the availability of the test. The ST is currently recommended mainly to determine exercise capacity and blood pressure (BP) amplitude, to reveal arrhythmias, and to establish risk in selected patients or when functional testing is not available. In asymptomatic patients, for whom CAD cannot be ruled out by a clinical assessment, stress imaging or CTA is recommended [2] (Table I).

### Non-pharmacological treatment

The 2013 and 2019 guidelines focus a lot on the role of lifestyle changes and non-pharmacological treatment. Recommendations on smoking prohibition, diet, and nutrition have not changed significantly over the years. Although all recommendations emphasized the role of physical activity, the most recent guidelines recommend 30–60 minutes of moderate physical activity on most days of the week. The authors of the guidelines emphasize that even irregular activity is beneficial [2]. The doses of acceptable alcohol intake have changed. The 2013 guidelines recommended limiting alcoholic beverages intake to 2 units per day (20 g of alcohol per day) in men and 1 unit per day (10 g of alcohol per day) in non-pregnant women [4]. The authors of the most recent recommendations reduced the allowable amount of alcohol to 100 g/week or 15 g/day [2].

### Pharmacological treatment

The 2006 guidelines introduced two goals of pharmacological treatment. The first one included improving the
prognosis, while the second one included reducing the symptoms and/or ischemia [3]. To improve the prognosis, the importance of angiotensin converting enzyme (ACE) inhibitors has clearly increased, as confirmed by the randomized clinical trials EUROPA (EURopean trial On reduction of cardiovascular Events) [5, 6]. ACE inhibitors in patients with additional clinical indications such as hypertension, heart failure, and diagnosed CAD, ACE inhibitors were recommended in class IIa B. The first-line therapy to improve the prognosis included, in addition to ACE inhibitors, antiplatelet agents (acylsalicylic acid (ASA) and/or alternatively clopidogrel IIa B) and statins (I A). To improve the prognosis, β-blockers were mainly recommended for patients after myocardial infarction or with concomitant heart failure (I A) [3].

For symptom relief and the reduction of ischemia, the authors recommended short-acting nitroglycerin (I B) and β-blockers (I A) or, in case of their intolerance, calcium channel blockers (CCBs) (I A). The 2006 guidelines were quite groundbreaking because of the introduction of new drugs intended to reduce clinical symptoms: nicoandil as a potassium channel opener (I C), ivabradine as an If ion current blocker, trimetazidine as an anti-anginal metabolic agent (IIb B) [3].

The main pharmacotherapy goals of the 2013 guidelines included symptom relief and prevention of cardiovascular events [4]. To manage angina, in addition to short-acting nitrates (I B), β-blockers and/or CCBs were recommended as the first-line therapy to control heart rate frequency and clinical symptoms (I A). The addition of long-acting nitrates,
Table II. Changes in diagnostic methods in three consecutive ESC guidelines

| Pharmacotherapy                      | 2006                                  | 2013                                  | 2019                                  |
|--------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| **Recommendations for preventing cardiac events** |                                       |                                       |                                       |
| ACE-I, ARB                           | – In patients with angina and diagnosed CAD (IIa B) | – In patients with burdens (e.g. HF, HA, or DM) (IA) | – In patients with burdens (e.g. HF, HA, or DM) (IA) |
|                                      | – In patients with burdens of HA, HF, post-MI status with LV dysfunction, DM (IA) |                                        | – In patients at a very high risk of CV events (IIa A) |
| ASA                                  | – In all patients without contraindications (IA) | – ASA at a dose of 75-150 mg/day in all patients with stable CAD (IA) | – ASA at 75–100 mg/day in patients after MI or with a history of revascularization (IA) |
| Other anti-coagulants                | – Clopidogrel for contraindications for ASA (IIa B) | – Clopidogrel for contraindications for ASA (IIa B) | – Clopidogrel for contraindications for ASA (IIa B) |
|                                      | – Adding a second thrombolytic drug (clopidogrel/prasugrel/rivaroxaban/ticagrelor) to ASA in patients at a high ischemic risk and the absence of a high bleeding risk (IIa A) | | |
| Statins and other hypolipidemic drugs| – Statins in all patients with coronary artery disease (IA) (treatment goal LDL-C < 2.5 mmol/l (96 mg/dl)) | – Statins in all patients with coronary artery disease (IA) (treatment goal LDL-C < 1.8 mmol/l (70 mg/dl) or a reduction by > 50%) | – Statins in all patients with CCS (IA) (in patients with a very high risk of CV events, the treatment goal of LDL-C < 55 mg/dl or a reduction > 50% of the baseline level of 1.8–3.5 mmol/l (70–135 mg/dl)) |
|                                      | – Fibrates in patients with low HDL-C and high TG, with DM and/or MS (IIb B) |                                        | – Adding ezetimibe if the treatment goal of statin therapy alone at the maximum tolerated dose is not achieved (IIb A) |
|                                      | – Adding a second thrombolytic drug (clopidogrel/prasugrel/rivaroxaban/ticagrelor) to ASA in patients at a high ischemic risk and the absence of a high bleeding risk (IIa A) |                                        | – Adding a PCSK9 inhibitor if target lipid concentrations are not achieved in very high-risk patients on the maximum tolerated dose of statins in combination with ezetimibe (IIa A) |

**Recommendations on the use of anti-ischemic drugs**

| β-Blockers                          | – In patients after MI or with HF (IA) | – BB and/or CCB as first-line drugs for HR and symptom control (IA) | – BB and/or CCB as first-line drugs to control HR and symptoms (IA) |
| CCB                                 | – CCB in case of lack of effect of BB or their intolerance (IA) | – To relieve symptoms and reduce ischemia (IB) | – Association of BB and DHP-CCB as the first-line therapy (IIa B) |
| Short-acting nitrates               | – Nitroglycerin to relieve symptoms and reduce ischemia (IB) | – Second-line addition of long-acting nitrates, ivabradine, nicardipil, or ranolazine, depending on HR, BP, and tolerability (IIa B) | – First-line therapy, in case of intolerance or insufficient effect of BB and/or CCB (IIa B) |
| Long-acting nitrates                | – In monotherapy for BB intolerance (IC) | – For an immediate relief of angina symptoms (IB) | – Nicorandil, ranolazine, ivabradine, or trimetazidine in the second-line setting to reduce angina symptoms and improve exercise tolerance if BB, CCB, and long-acting nitrates are contraindicated, poorly tolerated, or insufficient to control angina (IIa B) |
| Other drugs                         | – Nicorandil in monotherapy for BB intolerance (IC) | – Vasodilator and reduce ischemia and improve exercise tolerance (IIa B) | |
| Metabolic drugs                     | – Trimetazidine added to therapy to reduce ischemic symptoms or as a substitute if the primary therapy is intolerable (IIb B) | – Trimetazidine as part of the second-line therapy (IIb B) | |

ASA – acetylsalicylic acid, ACE-I – angiotensin-converting enzyme inhibitor, ARB – angiotensin receptor blocker, BB – β-blocker, BP – blood pressure, CAD – coronary artery disease, CCB – calcium channel blocker, CCS – chronic coronary syndrome, CV – cardiovascular, DHP – dihydropyridine, DM – diabetes mellitus, HA – hypertension, HDL-C – high-density lipoprotein fraction cholesterol, HR – heart rate, LDL-C – low-density lipoprotein fraction cholesterol, LV – left ventricle, MI – myocardial infarction, MS – metabolic syndrome, PCSK9 – proprotein convertase subtilisin/kexin type 9, TG – triglycerides.
ivabradine, nicorandil, or ranolazine, depending on heart rate frequency, blood pressure, and tolerability (IIa B), or trimetazidine (IIb B) was recommended as the second-line therapy drug [4].

For the prevention of cardiovascular events, the 2013 guidelines were not significantly different from the 2006 recommendations that included improving the prognosis. All patients with stable CAD were recommended to be administered a low dose of ASA (I A) or, if intolerable, alternatively clopidogrel (I B), statin (I A), and an ACE inhibitor or angiotensin receptor antagonist, if other conditions such as heart failure, hypertension, or diabetes (I A) were present [4].

The latest 2019 guidelines introduced significant changes not only in nomenclature, but also in pharmacotherapy. The overarching goals of treatment remained unchanged: the relief of angina symptoms and the prevention of cardiovascular events [2]. Short-acting nitrates (I B) have remained recommended for the relief of coronary symptoms in the presence of exertional angina. The new recommendations strengthened the importance of β-blockers and CCBs as first-line drugs in controlling heart rate frequency and symptoms (I A). If the use of a β-blocker or CCB has not provided sufficient control of angina symptoms, the guideline authors recommend considering a combination of a β-blocker and a dihydropyridine CCB (IIa C) as the first-line treatment (Iia B). The guidelines recommend that the second-line treatment includes the use of long-acting nitrates (Iia B), nicorandil, ranolazine, ivabradine, and trimetazidine in patients for whom the treatment with β-blockers, CCBs, and long-acting nitrates is contraindicated, poorly tolerated, or insufficient to control angina symptoms (Ila B) [2].

Multiple changes have been introduced in the recommendations for the prevention of cardiovascular events. As a matter of long-term secondary prevention in patients at a high risk of ischemic events and without a high risk of bleeding, the guidelines recommended considering adding a second anticoagulant to ASA (75–100 mg/day), notwithstanding the concomitant sinus rhythm (Ila A). A high risk of ischemic events was defined as disseminated multivessel CAD, with at least one of the following conditions: diabetes mellitus requiring pharmacological treatment, recurrent myocardial infarction, peripheral arteriosclerosis, or chronic kidney disease with a filtration rate of 15–59 ml/min/1.73 m² [2]. Dual antithrombotic treatment should include a second antiplatelet drug (clopidogrel 75 mg/day, prasugrel 5 or 10 mg/day, or ticagrelor 60 mg twice daily) or rivaroxaban administered at a dose of 2.5 mg twice daily [2].

In patients with non-valvular atrial fibrillation and indications for anticoagulation therapy, non-vitamin K anticoagulant oral anticoagulants (NOACs) are recommended preferentially to vitamin K antagonists (VKAs) (I A). In patients who tolerate NOACs, apixaban 5 mg twice daily, dabigatran 150 mg twice daily, or rivaroxaban 20 mg once daily is recommended instead of VKAs in combination with an antiplatelet therapy. If the high risk of bleeding outweighs the risk of stent thrombosis or an ischemic stroke during a single or dual antiplatelet therapy, it is recommended to consider rivaroxaban 15 mg once daily or dabigatran 110 mg twice daily (Ila B). A proton pump inhibitor is recommended for patients receiving ASA, a dual antiplatelet therapy, or anticoagulant monotherapy, who are at a high risk of gastrointestinal bleeding (I A). The recent guidelines have introduced significant changes in LDL cholesterol targets for patients at a very high cardiovascular risk, with LDL cholesterol targets below 55 mg/dl. In addition to lifestyle changes, an intensive hypolipidemic treatment should be introduced to achieve the recommended values. Statins (I A) are recommended for all patients with CCS. A novelty in the recent guidelines involves the addition of ezetimibe to the maximum tolerated statin dose (I B), should the target lipid concentrations not be achieved. If the target lipid concentrations are still not achieved in very high-risk patients using the maximum tolerated dose of statins in combination with ezetimibe, the addition of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is recommended (I A) [2].

The authors of the guidelines point to new groups of hypoglycemic drugs recommended for patients with diabetes and a concomitant CCS. Sodium-glucose cotransporter 2 inhibitors (empagliflozin, canagliflozin, or dapagliflozin) and glucagon-like peptide 1 receptor agonists (lixisenatide or semaglutide) are recommended (I A) in patients with cardiovascular disease and diabetes [2] (Table II).

Conclusions

Over the past 15 years, three updates of the guidelines for the management of stable coronary artery disease (currently chronic coronary syndromes) have been published. The rapid progress of medicine has caused significant changes in the diagnosis and non-invasive treatment. The reduction of clinical symptoms and the prevention of cardiovascular incidents remain the most important goals of treatment.

Disclosure

The authors report no conflict of interest.

References

1. Kosnicki MA. Ischemic heart disease in Poland and the world – a fully unresolved problem. Fact-Based Cardiology 2010; 1: 35–48.
2. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott C, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edwards F, Escaned J, Gersh BJ, Sølvberg P, Gilard M, Hasdal D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J 2020; 41: 407–77.
3. Fox K, García MA, Ardiglione G, Bussmann P, Caretti F, Ceccherini G, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc J, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
4. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pflisterer M, Prescot E, Ruschitzka F, Sabaté M, Senior R, Taggart DP, van der Wall EE, Vrints CJM, ESC Committee for Practice Guidelines; Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Kruyt J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document Reviewers; Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff M, Erol C, Frank H, Funck-Brentano C, Gaemperli O, González-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Rydén L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirim A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.

5. Fox KM Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.

6. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1: 18-20.